Authors: Eckhardt, SG Rizzo, J Sweeney, KR Cropp, G Baker, SD Kraynak, MA Kuhn, JG Villalona-Calero, MA Hammond, L Weiss, G Thurman, A Smith, L Drengler, R Eckardt, JR Moczygemba, J Hannah, AL Von Hoff, DD Rowinsky, EK

Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104

Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML

Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696